Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9342265 | 0.81 | RXRA (0.51) | PPARGALDH1A1NPC1RAB9A | |
| SCHEMBL5918964 | 0.80 | MAOB (0.50) | PPARGALDH1A1KMT2A | |
| SCHEMBL7384539 | 0.80 | ACE (0.58) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL2937753 | 0.78 | HDAC3 (0.42) | PPARAPPARGHDAC1HDAC3HDAC2 | |
| SCHEMBL3842089 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1GAAMEN1NPC1RAB9A | |
| SCHEMBL864308 | 0.77 | HDAC1 (0.61) | PPARGHDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL7795392 | 0.76 | KCNA5 (0.45) | PPARAPPARGHDAC1NAMPTMEN1 | |
| SCHEMBL31160269 | 0.76 | SIRT2 (0.47) | TLR7HDAC1 | |
| SCHEMBL14558984 | 0.76 | GLS (0.48) | HDAC1NAMPTMEN1KMT2ACTSK | |
| SCHEMBL7813239 | 0.76 | PPARG (0.36) | PPARAPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| EP-1601384-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | Amersham Health AS (NO) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080492-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | AMERSHAM HEALTH AS (NO) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | PPARA 3717/4885PPARG 3509/4885TLR7 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.